Under Armour's revenue falls, missing earnings estimates, as it focuses on brand repositioning and cost-cutting amid inflation and weaker consumer spending.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Appeals court overturns contempt order against Trump officials for deporting Venezuelan migrants, citing executive authority.
Under Armour's revenue falls, missing earnings estimates, as it focuses on brand repositioning and cost-cutting amid inflation and weaker consumer spending.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
Appeals court overturns contempt order against Trump officials for deporting Venezuelan migrants, citing executive authority.